Legend Biotech Corporation (LEGN) Key Metrics
LEGN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.59B
- Enterprise value
- $2.90B
- P/E (TTM)
- —
- Forward P/E
- 27.5
- PEG ratio
- —
- Price / sales
- 2.8 10-yr median 40.8
- Price / book
- 2.9 10-yr median 7.1
- EV / EBITDA
- 252.3
- Dividend yield
- —
- Beta
- 0.57
LEGN key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsLEGN valuation Price multiples at each fiscal year-end price.
Price / sales−58.9%
3.9
2025 · hover or tap a bar for each year
20172025
Price / book−30.1%
4.0
2025 · hover or tap a bar for each year
20172025
Free cash flow yield−1.5 pts
−4.2%
2025 · hover or tap a bar for each year
20172025
LEGN returns How much profit the business earns on the capital it uses.
Return on equity−13.6 pts
−29.1%
2025 · hover or tap a bar for each year
20172025
Return on invested capital+59.4 pts
−29.3%
2025 · hover or tap a bar for each year
20172025
Return on assets−7.4 pts
−17.4%
2025 · hover or tap a bar for each year
20172025
Free cash flow margin+8.9 pts
−16.3%
2025 · hover or tap a bar for each year
20172025
Asset turnover+69.6%
0.60
2025 · hover or tap a bar for each year
20172025
LEGN per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+62.7%
$5.58
2025 · hover or tap a bar for each year
20172025
Earnings per share
−$1.61
2025 · hover or tap a bar for each year
20172025
Free cash flow per share
−$0.91
2025 · hover or tap a bar for each year
20172025
Book value per share−4.5%
$5.44
2025 · hover or tap a bar for each year
20172025
Shares outstanding+0.8%
184.3M
2025 · hover or tap a bar for each year
20172025
LEGN financial health Debt, liquidity and how easily interest is covered.
Debt / equity+22.5%
0.41
2025 · hover or tap a bar for each year
20172025
Net debt+$237.2M
−$534.9M
2025 · hover or tap a bar for each year
20172025
Current ratio−57.6%
1.96
2025 · hover or tap a bar for each year
20172025
Interest coverage
-6.4
2025 · hover or tap a bar for each year
20172025
Debt / assets+13.7%
0.24
2025 · hover or tap a bar for each year
20172025
LEGN efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−15 days
67 days
2025 · hover or tap a bar for each year
20172025
Days of inventory−9 days
25 days
2025 · hover or tap a bar for each year
20172025
Days payables outstanding+8 days
53 days
2025 · hover or tap a bar for each year
20172025
Cash conversion cycle−33 days
39 days
2025 · hover or tap a bar for each year
20172025
Capex / revenue+4.3 pts
6.6%
2025 · hover or tap a bar for each year
20172025
LEGN valuation history
Fiscal year-endToday9-year median
LEGN returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
LEGN debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
LEGN price vs earnings per share
Share price at year-endEPS (right axis)
LEGN key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $4.01B | $5.95B | $10.59B | $7.94B | $6.57B | $3.33B | — | — | — |
| Enterprise value | $3.47B | $5.18B | $9.61B | $7.20B | $5.81B | $2.82B | — | — | — |
| Price / sales | 3.9 | 9.5 | 37.2 | 67.9 | 95.4 | 44.4 | — | — | — |
| Price / book | 4.0 | 5.7 | 8.5 | 10.7 | 8.6 | 5.6 | — | — | — |
| EV / sales | 3.4 | 8.3 | 33.7 | 61.5 | 84.4 | 37.7 | — | — | — |
| Earnings yield | −7.4% | −3.0% | −4.9% | −5.6% | −6.1% | −8.0% | — | — | — |
| Free cash flow yield | −4.2% | −2.7% | −3.9% | −2.8% | −3.7% | −7.6% | — | — | — |
| Share price at fiscal year-end | $21.74 | $32.54 | $60.17 | $49.92 | $46.61 | $28.16 | — | — | — |
| Per share | |||||||||
| Revenue per share | $5.58 | $3.43 | $1.62 | $0.74 | $0.49 | $0.63 | $0.47 | $0.49 | $0.18 |
| Earnings per share | −$1.61 | −$0.97 | −$2.94 | −$2.81 | −$2.87 | −$2.25 | −$0.77 | −$0.03 | $0.07 |
| Operating cash flow per share | −$0.55 | −$0.79 | −$2.23 | −$1.27 | −$1.41 | −$1.89 | −$0.63 | $3.07 | −$0.02 |
| Free cash flow per share | −$0.91 | −$0.86 | −$2.36 | −$1.41 | −$1.73 | −$2.14 | −$0.93 | $2.86 | −$0.02 |
| Cash per share | $5.15 | $6.14 | $7.43 | $6.45 | $6.26 | $4.28 | $1.20 | $2.16 | $0.02 |
| Book value per share | $5.44 | $5.69 | $7.11 | $4.68 | $5.44 | $5.06 | −$0.93 | $0.09 | $0.09 |
| Tangible book value per share | $5.03 | $4.74 | $7.08 | $4.25 | $5.32 | $5.08 | −$0.97 | $0.09 | $0.09 |
| Capex per share | $0.37 | $0.08 | $0.13 | $0.14 | $0.32 | $0.26 | $0.30 | $0.21 | $0.01 |
| Debt per share | $2.24 | $1.92 | $1.87 | $1.79 | $0.87 | $0.03 | $0.05 | $0.04 | $0.00 |
| Shares outstanding | 184.3M | 182.9M | 176.1M | 159.0M | 140.9M | 118.2M | 132.0M | 100.2M | 132.0M |
| Change in shares outstanding | +0.8% | +3.8% | +10.7% | +12.9% | +19.2% | −10.5% | +31.7% | −24.1% | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −29.1% | −15.4% | −51.9% | −59.1% | −59.2% | −112.2% | — | −26.7% | 77.0% |
| Return on invested capital (ROIC) | −29.3% | −88.8% | −252.9% | — | −608.2% | — | — | — | 90.4% |
| Return on assets (ROA) | −17.4% | −10.1% | −32.6% | −36.4% | −43.8% | −52.8% | −28.3% | −0.8% | 3.9% |
| Return on tangible assets | −17.9% | −11.8% | −28.1% | −35.4% | −36.6% | −36.8% | −36.0% | −0.6% | 3.9% |
| Free cash flow margin | −16.3% | −25.2% | −145.9% | −191.1% | −354.3% | −337.7% | −197.8% | 583.4% | −13.8% |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | — | −0.25 |
| Financial health | |||||||||
| Total debt | $413.7M | $350.6M | $328.7M | $284.5M | $123.0M | $3.7M | $6.1M | $4.3M | $269,000 |
| Cash & short-term investments | $948.6M | $1.12B | $1.31B | $1.03B | $882.4M | $506.1M | $158.9M | $216.2M | $2.1M |
| Net debt | −$534.9M | −$772.1M | −$980.0M | −$741.1M | −$759.4M | −$502.4M | −$152.8M | −$211.9M | −$1.8M |
| Debt / equity | 0.41 | 0.34 | 0.26 | 0.38 | 0.16 | 0.01 | — | 0.50 | 0.02 |
| Debt / assets | 0.24 | 0.21 | 0.18 | 0.21 | 0.11 | 0.01 | 0.02 | 0.01 | 0.00 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | −0.13 |
| Current ratio | 1.96 | 4.62 | 6.92 | 3.69 | 4.14 | 5.14 | 1.62 | 2.05 | 4.43 |
| Quick ratio | 1.91 | 4.54 | 6.83 | 3.66 | 4.14 | 5.12 | 1.61 | 2.05 | 4.43 |
| Interest coverage | -6.4 | -14.0 | -20.2 | -42.2 | -435.9 | -74.4 | -594.2 | -18.7 | — |
| Working capital | $610.7M | $1.01B | $1.28B | $801.3M | $720.6M | $478.4M | $79.3M | $167.8M | $178.8M |
| Invested capital | $467.2M | $268.5M | $271.3M | $3.2M | $6.5M | $95.4M | −$275.7M | −$203.2M | $10.3M |
| Tangible asset value | $927.5M | $866.3M | $1.25B | $675.6M | $749.1M | $601.8M | −$128.0M | $8.6M | $12.2M |
| Net current asset value | $515.5M | $654.3M | $900.6M | $512.5M | $596.3M | $471.7M | −$203.5M | −$93.4M | $4.4M |
| Graham number | — | — | — | — | — | — | — | — | $0.38 |
| Graham net-net per share | $2.28 | $3.27 | $4.76 | $3.00 | $4.07 | $3.78 | −$1.70 | −$1.22 | −$0.40 |
| Capital allocation | |||||||||
| Share buybacks (net) | — | — | — | — | — | — | — | — | $0 |
| Capex / revenue | 6.6% | 2.2% | 8.0% | 19.0% | 66.0% | 40.4% | 63.4% | 42.8% | 3.8% |
| Capex / operating cash flow | — | — | — | — | — | — | — | 6.8% | — |
| Capex / depreciation | 2.34 | 0.60 | 1.11 | 1.21 | 3.26 | 3.05 | 7.44 | 12.49 | 4.09 |
| Stock-based compensation / revenue | 6.3% | 11.0% | 16.7% | 29.3% | 29.3% | 6.3% | 2.1% | 1.4% | — |
| R&D / revenue | 40.3% | 65.9% | 134.0% | 286.9% | 455.3% | 309.5% | 262.0% | 123.4% | 34.7% |
| SG&A / revenue | 33.2% | 45.3% | 70.5% | 148.8% | 217.2% | 30.8% | 52.4% | 8.0% | 6.9% |
| Efficiency | |||||||||
| Days sales outstanding | 66.5 | 82.0 | 129.0 | 160.8 | 374.3 | 288.0 | 426.2 | 1,252.9 | 3,538.7 |
| Days of inventory on hand | 25.0 | 33.7 | 37.7 | 33.8 | 2.1 | 2.3 | — | — | -41.8 |
| Days payables outstanding | 52.9 | 44.6 | 65.6 | 108.2 | 7.0 | 11.4 | — | — | -16,482.0 |
| Cash conversion cycle (days) | 38.6 | 71.1 | 101.1 | 86.4 | 369.4 | 279.0 | — | — | 19,978.9 |
| Receivables turnover | 5.48 | 4.45 | 2.83 | 2.27 | 0.98 | 1.27 | 0.86 | 0.29 | 0.10 |
| Payables turnover | 6.89 | 8.18 | 5.56 | 3.37 | 52.43 | 32.03 | 0.00 | 0.00 | −0.02 |
| Inventory turnover | 14.60 | 10.83 | 9.68 | 10.80 | 176.58 | 157.02 | 0.00 | 0.00 | −8.73 |
| Asset turnover | 0.60 | 0.36 | 0.18 | 0.10 | 0.07 | 0.15 | 0.17 | 0.15 | 0.10 |
| Average receivables | $187.6M | $141.0M | $100.8M | $51.5M | $70.6M | $59.2M | $72.2M | $168.7M | $228.7M |
| Average payables | $59.2M | $28.7M | $25.9M | $19.4M | $6.0M | $7.2M | $8.5M | $5.8M | $4.3M |
| Average inventory | $28.0M | $21.7M | $14.9M | $6.1M | $1.8M | $1.5M | $1.1M | $573,000 | $11,000 |
| Intangibles / total assets | 4.3% | 10.4% | 0.2% | 5.2% | 1.5% | −0.3% | 1.8% | 0.0% | 0.0% |
Computed from LEGN's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
LEGN valuation and financial ratios
Legend Biotech earned a return on equity of −29.1% and a return on invested capital of −29.3% in fiscal 2025. It ended the year with $413.7 million of debt and $948.6 million in cash and short-term investments, a net cash position of $534.9 million. The share count rose 39.6% from 132.0M to 184.3M over 8 years.
See the LEGN income statement, the LEGN chart for price history, or the LEGN stock overview for the latest quote and news.
LEGN key metrics FAQ
What is Legend Biotech's return on equity?
Legend Biotech's return on equity (ROE) was −29.1% in fiscal 2025: net income of -$296.8 million on average shareholders' equity of $1.0 billion.
What is Legend Biotech's ROIC?
Legend Biotech's return on invested capital was −29.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Legend Biotech have?
Legend Biotech had total debt of $413.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.41 and more cash than debt.
What is Legend Biotech's free cash flow yield?
Legend Biotech generated -$168.0 million of free cash flow in fiscal 2025, a free cash flow yield of −4.2% on its market value at year-end ($4.0 billion).
What is Legend Biotech's current ratio?
Legend Biotech's current ratio was 1.96 at the end of fiscal 2025: current assets were 1.96 times current liabilities.